Cirrus Logic Inc. (CRUS) Drops 5.89% on January 05

Equities Staff |

Cirrus Logic Inc. (CRUS) was one of the Russell 2000's biggest losers for Tuesday January 05 as the stock slid 5.89% to $27.58, a loss of $-1.725 per share. Starting at an opening price of $29.48 a share, the stock traded between $27.52 and $29.54 over the course of the trading day. Volume was 2.9 million shares over 19,532 trades, against an average daily volume of 1.84 million shares and a total float of 63.7 million.

The losses send Cirrus Logic Inc. down to a market cap of $1.76 billion. In the last year, Cirrus Logic Inc. has traded between $38.20 and $22.63, and its 50-day SMA is currently $31.28 and 200-day SMA is $32.32.

The stock has a P/E Ratio of 17.1.

Cirrus Logic Inc develops high-precision, analog and mixed-signal integrated circuits (ICs) for a range of audio and energy markets.Its main product line includes audio products and energy products.

Cirrus Logic Inc. is based out of Austin, TX and has some 1,104 employees. Its CEO is Jason P. Rhode.

For a complete fundamental analysis analysis of Cirrus Logic Inc., check out Equities.com’s Stock Valuation Analysis report for CRUS. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets

Ozobot by Evollve Inc

Ozobot is a world leader in compact super intelligent robots that entertain and educate through fun interactive gaming.

GoCoin

Blockchain currencies (e.g. Bitcoin) provide a new disruptive way to transfer value between parties over the internet as opposed to going through banks. GoCoin provides online merchants with a suite…